Overview : BSI-082 is a best-in-class, highly differentiated fully human anti-SIRPα antagonist monoclonal antibody. It shows strong binding activity to huSIRPα variant V1/V2/V8. BSI-082 specifically binds to SIRPα and does not bind to SIRPβ or SIRPγ, and potently blocks the interaction of SIRPα to CD47. Blocking SIRPα enables tumor associated macrophages and dendritic cells to resume their phagocytosis activity and destroy tumor. Biosion has global rights to develop and commercialize BSI-082.

Development status : Pre-clinical development, IND filing expected in 2H 2023